| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117951 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US8410077 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9750822 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9200088 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US7635773 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US10322139 | SAGE THERAP | Neuroactive steroid formulations and methods of treating CNS disorders |
Jan, 2033
(8 years from now) | |
| US10251894 | SAGE THERAP | Anticonvulsant activity of steroids |
Nov, 2033
(9 years from now) | |
| US10940156 | SAGE THERAP | Neuroactive steroids, compositions, and uses thereof |
Mar, 2037
(12 years from now) | |
Zulresso is owned by Sage Therap.
Zulresso contains Brexanolone.
Zulresso has a total of 8 drug patents out of which 0 drug patents have expired.
Zulresso was authorised for market use on 17 June, 2019.
Zulresso is available in solution;intravenous dosage forms.
Zulresso can be used as method of treating postpartum depression.
Drug patent challenges can be filed against Zulresso from 18 June, 2023.
The generics of Zulresso are possible to be released after 08 March, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| New Patient Population(NPP) | Jun 16, 2025 |
Drugs and Companies using BREXANOLONE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Method of treating postpartum depression
Dosage: SOLUTION;INTRAVENOUS
ZULRESSO family patents
